Clinical impact Target hospitals with high sepsis burden and bloodstream infection rates to demonstrate the value of rapid pathogen identification via PNA FISH, highlighting reductions in mortality, shorter hospital stays, and lower costs.

Adoption readiness Leverage AdvanDx's position as a market leader in molecular testing of positive blood cultures to pursue labs seeking to shorten reporting times from 48 to 72 hours, emphasizing improved antibiotic decision-making.

Expansion opportunities Identify mid to large hospitals and health systems expanding microbiology capabilities and investing in rapid diagnostics, offering scalable PNA FISH solutions across multiple wards and bloodstream infection workflows.

Financial alignment Position value around cost savings from reduced LOS and optimized antibiotic use to align with hospital budgeting cycles and potential payor incentives for antibiotic stewardship programs.

Strategic partnerships Explore collaborations with hospital procurement, infectious disease leadership, and stewardship committees to drive adoption, pilot programs, and evidence generation that supports broader implementation.